eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
3/2015
vol. 66
 
Share:
Send email
Share:
abstract:
Original paper

CD99 correlates with low cyclin D1, high topoisomerase 2 status and triple negative molecular phenotype but is prognostically irrelevant in breast carcinoma

Piotr Czapiewski
,
Marzena Wełnicka-Jaśkiewicz
,
Barbara Seroczyńska
,
Jarosław Skokowski
,
Aleksandra Sejda
,
Jolanta Szade
,
Claudia Wiewiora
,
Wojciech Biernat
,
Anna Żaczek

Pol J Pathol 2015; 66 (3): 269-275
DOI: https://doi.org/10.5114/pjp.2015.54961
Online publish date: 2015/10/23
View full text Get citation
 
PlumX metrics:
CD99 is a protein initially described in the Ewing sarcoma family of tumors, but growing evidence has shown its expression in other tumors of mesenchymal, hematopoietic and even epithelial origin. Some articles report CD99 in metaplastic carcinoma of the breast, a subtype of breast carcinoma (BC) with pronounced epithelial to mesenchymal (EMT) phenotype. Our aim was to analyse the potential relationship between CD99 and selected EMT (vimentin, E-cadherin, Twist) and proliferation markers (Ki-67, c-myc, cyclin D1, topoisomerase 2), molecular subtypes of BC, as well as overall survival (OS) and progression-free survival (PFS).

In a group of 122 cases CD99 membrane expression was seen in 14 (11.5%) cases: strong in 11 (9%) and moderate in 3 (2.5%). Expression of CD99 correlated with low cyclin D1 index, high level of topoisomerase 2 expression and lack of progesterone receptor (PR) but not with EMT characteristics. Additionally, strong expression of CD99 correlated with triple negative molecular BC phenotype. CD99 was prognostically irrelevant for OS and PFS.

CD99 correlates with selected proliferative markers and low ER/PR receptor status but not with patients’ outcome in BC. Further studies are required to explain precisely its role in molecular pathogenesis of BC.
keywords:

breast carcinoma, CD99, epithelial to mesenchymal transition, cyclin D1
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.